key: cord-0955130-2rfvj52p
authors: Kakkanattu, Tom Jose; Sankarasubbaiyan, Suresh; Yadav, Ashok K.; Kundu, Monica; Gowda BG, Mallikarjuna; Kumar, Vivek; Shah, Kamal; Jha, Vivekanand
title: Outcome and Determinants of Outcome of COVID-19 Infection amongst Hemodialysis Patients: Findings from a National Dialysis Network Program in India
date: 2021-03-15
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.03.003
sha: 2477c440b6d128d309692c888bcddd9c6ddda700
doc_id: 955130
cord_uid: 2rfvj52p

nan

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the causative agent of the COVID-19 pandemic, has infected nearly 86 million people and caused more than 180,000 deaths worldwide. Patients with pre-existing conditions including those with CKD are at increased risk of adverse outcomes due to this infection. In the US, the risk of COVID-19 infection was 3.5 times greater among Medicare ESRD beneficiaries compared to all fee-forservice beneficiaries. Dialysis patients, already at high risk for a variety of complications, in particular cardiovascular disease, are also at an increased risk of adverse outcomes secondary to COVID-19 because of age, comorbidities like diabetes, hypertension and the need for multiple hospital contacts for dialysis. Most reports of COVID-19 in dialysis patients are from the USA and Europe, and the impact of the pandemic on dialysis patients in the developing world is lacking. [1] [2] [3] [4] Initial reports from India highlighted the large-scale hardships faced by the patient on dialysis inability to access treatment during the prolonged period of nationwide lockdown leading to missed treatments and dropouts. 5, 6 In this article, we report the outcomes of patients diagnosed with COVID-19 in-center in a large hemodialysis network in India.

Out of a total 14,573 patients who received dialysis in the network centers during the entire study period, 1279 subjects were found to be positive for SARS-CoV 2. Table 1 (Table 3) .

This is the first systematic report of the impact of COVID-19 on the outcomes of patients on incentre hemodialysis from the developing world. In the absence of a national dialysis registry, this analysis from a large cohort comes closest to a nationwide representation of the health effects of this pandemic in India. We found that the prevalence of infection was 20-fold greater in this population compared to that reported in the general population in India during this period (8.7% and 0.44% respectively). This is greater than that described in the REIN registry data from France (3.3% v 0.2%). 1 In addition to the increase in risk due to repeated contact with the health care system, the higher prevalence could also be contributed by opportunities for more frequent screening and testing. The male predominance likely reflects the male dominance in the general dialysis population. An overwhelming proportion (99%) of the COVIDpositive patients in this cohort were admitted to hospitals in compliance with local policies. The COVID-19 surge in India followed those in China, Western Europe and North America. This allowed the Indian centers to rapidly adopt the best practices implemented in dialysis centers in those parts of the world. There were some unique challenges, however, related to the Indian healthcare system, such as the closure of units in certain hospitals that were converted into COVID hospitals and other centers turning COVID positive patients away because of lack of resources that produced additional hardships for dialysis patients in India. 5, 6 About 30% of COVID-19 positive patients had been referred from other dialysis centers.

About a quarter of all COVID-positive dialysis patients died. This mortality rate is comparable to that reported by other studies on hemodialysis patients from high-income countries, despite the Indian dialysis population being younger and having a lower prevalence of comorbidities.

The mortality was indeed much greater than the COVID-19 case fatality rate amongst the general population of India (1.45%). However, the mortality rate among non-COVID patients during the study period in the network was 19.26%, which suggests that the excess mortality in the COVID-positive population was just about 3.7%. The mortality in the NephroPlus dialysis cohort during the corresponding period in 2019 was 15%, suggesting that the impact of COVID-19 during the study period was not limited to those who were infected with the virus. Our finding confirms the high mortality reported amongst dialysis patients in general during the pandemic, 5, 7 attributable due to other factors related to the pandemic or the lockdown like difficulty in transport, closure of dialysis facilities, reduced dialysis frequency, decreased inpatient and outpatient care, and financial difficulties especially.

As expected, elderly males, those with diabetes, hypertension, pre-existing heart disease, and those with longer dialysis vintage were at increased risk of mortality. The mortality risk factors are similar to those reported in other studies amongst the dialysis population and general population studies from India.

J o u r n a l P r e -p r o o f 5 The strength of our study includes nationwide coverage with a large population base who were screened using a uniform protocol, and the completeness of outcome data. We show that despite relatively limited resources, it was possible to implement COVID protocols in dialysis units. This is important because in-center dialysis is the overwhelming dialysis modality during COVID-19 in India, with very low penetration of home dialysis and an almost complete stoppage of transplantation. 8 There are some limitations, however. Though the network had a uniform temperature and symptom screening protocol prior to unit entry, the implementation might have differed based on local practice adherence. The absence of universal screening might have led to missing out of asymptomatic individuals and an overestimation of case fatality rates.

The protocols for screening during the study period were constrained by government directives, local preferences, access to testing and self-reporting of symptoms. A small study of COVID dialysis from Mumbai had shown that more than 50% of patients were asymptomatic or had mild disease. 7 Finally, we did not have data on the severity of COVID-19 infection and treatment protocols in the individuals.

In view of the ongoing surges, the threat by the pandemic will remain significant for this vulnerable population. This can be minimized by liberal testing protocols and persisting with steps intended to minimize disease transmission. COVID vaccination program started in India on January 16, 2021. Appropriately, the healthcare workers and the elderly are being prioritized. Given the high risk of death, especially amongst the younger population on dialysis, experts have called for prioritization of dialysis patients for vaccination before other high-risk groups such as the obese and smokers and those with heart disease and obesity. 9 It is worth pointing out that a significant proportion of tobacco users use chewing tobacco, which does not cause lung injury to the same extent as smoking.

To conclude, our study confirms that the in-center dialysis population has a high risk of acquiring COVID-19 infection and has poor outcomes once infected. Our study reinforces the need to implement strict measures targeting personal protection as well as the need to find J o u r n a l P r e -p r o o f evidence-based approaches to prevent the development of COVID-19 in this high-risk population.

SS, MGB and KDS are employed by NephroPlus. VJ has research grants from Baxter, GSK and reports Consultancy and Advisory Board honoraria from Baxter Healthcare, and AstraZeneca, outside the published work. All other authors reported no conflict. 

Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

COVID-19 in dialysis patients: outlasting and outsmarting a pandemic

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Outcomes of patients with end-stage kidney disease hospitalized with COVID-19

The Adverse Effect of COVID Pandemic on the Care of Patients With Kidney Diseases in India

Adding insult to injury: kidney replacement therapy during COVID-19 in India

Impact of COVID-19 on maintenance haemodialysis patients: The Indian scenario

The state of nephrology in South Asia

The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action

Supplementary information is available at KI Report's website